financetom
Business
financetom
/
Business
/
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Prinses Máxima Center for Pediatric Oncology Implements Callisto™ from Volta Labs to Streamline Clinical Genomics Workflows
Sep 10, 2025 10:30 AM

BOSTON, Sept. 10, 2025 /PRNewswire/ -- Volta Labs today announced that the Prinses Máxima Center for Pediatric Oncology has acquired the Callisto™ platform to streamline sample preparation across multiple genomics workflows, supporting both Illumina and Oxford Nanopore Technologies (ONT) sequencing platforms.

The Prinses Máxima Center is the largest pediatric cancer center in Europe, dedicated to integrating care and research to improve outcomes for children with cancer. By adopting Callisto, the Center will advance sample preparation across multiple genomics workflows. This implementation will increase efficiency and reproducibility while reducing hands-on time for laboratory staff.

"Callisto's full walk-away automation for multiple sequencing approaches will allow us to establish Illumina whole-genome sequencing as a standard of care for all pediatric patients, while at the same time supporting the adoption of Oxford Nanopore sequencing for rapid diagnosis," said Bastiaan Tops, Head of Laboratory for Childhood Cancer Pathology at Prinses Máxima Center. "By simplifying complex sequencing workflows, Callisto frees our team to focus more of our time and expertise on what matters most—delivering better outcomes for children with cancer."

Callisto automates extraction, library preparation, and target enrichment in a compact, user-friendly system. Its flexibility enables clinical and research labs to streamline multiple sequencing applications across different platforms without requiring specialized technical expertise.

"Partnering with Prinses Máxima Center is an honor for us," said Udayan Umpathi, CEO of Volta Labs. "I was inspired to see how the team at Prinses Maxima is applying advanced genomic technologies as the standard of care, particularly for children with cancer. We are proud to collaborate in advancing technologies that bring insights to these patients faster."

The adoption of Callisto underscores the growing global demand for automation solutions that improve NGS efficiency, accuracy, and scalability.

About Prinses Máxima Center for Pediatric Oncology

The Prinses Máxima Center for Pediatric Oncology, located in Utrecht, The Netherlands, brings together the best possible care and scientific research for children with cancer. With a strong focus on innovation, collaboration, and excellence, the center aims to cure every child with cancer, with optimal quality of life.

About Volta Labs

Volta Labs is a genomics applications company that has developed a cutting-edge digital fluidics platform to maximize the performance and scalability of sample preparation in genomics while providing unparalleled consistency. For more information about our products and services, please visit www.voltalabs.com.

Media Contact

Nicole Ellis Ovadia

Director of Strategic Marketing

Volta Labs, Seaport, MA

[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/prinses-maxima-center-for-pediatric-oncology-implements-callisto-from-volta-labs-to-streamline-clinical-genomics-workflows-302551402.html

SOURCE Volta Labs Inc.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Confluent Explores Sale After Interest From Tech Firms, Private Equity
Market Chatter: Confluent Explores Sale After Interest From Tech Firms, Private Equity
Oct 8, 2025
03:59 AM EDT, 10/08/2025 (MT Newswires) -- Confluent (CFLT) is considering a possible sale after attracting interest from tech companies and private equity firms, Reuters reported Tuesday, citing three people familiar with the matter. The report said the company, with a market capitalization of about $7 billion, has begun working with an investment bank on the sale process, though it...
Joby Aviation Prices $514 Million Stock Offering
Joby Aviation Prices $514 Million Stock Offering
Oct 8, 2025
03:47 AM EDT, 10/08/2025 (MT Newswires) -- Joby Aviation ( JOBY ) said Tuesday it has priced a public offering of 30.5 million shares at $16.85 each for estimated gross proceeds of about $513.9 million. The underwriter has been granted a 30-day option to purchase up to about 4.6 million additional shares. Proceeds from the offering, expected to close Thursday,...
Nano Nuclear Energy Strikes Deal for $400 Million Share Offering
Nano Nuclear Energy Strikes Deal for $400 Million Share Offering
Oct 8, 2025
03:51 AM EDT, 10/08/2025 (MT Newswires) -- Nano Nuclear Energy ( NNE ) said late Tuesday it reached agreements with institutional investors for the purchase and sale of about 8.5 million of its shares through an oversubscribed private placement. The company expects to generate gross proceeds of $400 million from the offering, which is scheduled to close on or about...
AI fintech Optasia aims to raise $375 million in South African listing
AI fintech Optasia aims to raise $375 million in South African listing
Oct 8, 2025
JOHANNESBURG (Reuters) -Optasia, a fintech company partly owned by Ethos Capital, said on Wednesday it planned to list on South Africa's Johannesburg Stock Exchange and raise up to 6.3 billion rand ($375 million) by selling a combination of new and existing shares. The company, which operates AI-powered financial services in 38 countries, will raise about 1.3 billion rand in an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved